Direct-acting antivirals
64 articles
Have a Heart, Save My Liver! Why Hepatitis C Virus Care Remains Inaccessible
A policy brief, developed by TAG, presents online survey data from 23 countries on some of the key HCV diagnostics and policy barriers that inhibit access to HCV care in LMICs. More
Have a Heart, Save My Liver! Why Hepatitis C Virus Care Remains Inaccessible
A policy brief, developed by TAG, presents online survey data from 23 countries on some of the key HCV diagnostics and policy barriers that inhibit access to HCV care in LMICs. More
TAG Welcomes Addition of Ravidasvir to WHO Essential Medicines List for Treatment of Hepatitis C Virus
Ravidasvir is the first HCV cure to be developed through South-South collaboration and with funding and clinical support from non-profit organizations. It is now recommended for use in combination with sofosbuvir as an alternative pangenotypic DAA. More
The Impact of Expanded Access to DAAs for Hepatitis C Virus on Patient Outcomes in Canada
A study evaluated the early change in rates of HCV-related hospitalizations overall and HCV-related hospitalizations with hepatocellular carcinoma after expanded access to DAAs in Canada. More
Direct-Acting Antivirals Prove Long-Acting on HCV Infection after Liver Transplant
Long-term follow-up of direct-acting antiviral treatment of HCV infection after liver transplant shows persistent improvement in hepatic function, fibrosis, and survival rate. More
